Drug Profile
Research programme: potassium channel modulators - Pharmexa/Poseidon
Latest Information Update: 27 Mar 2007
Price :
$50
*
At a glance
- Originator Pharmexa; Poseidon Pharmaceuticals
- Class
- Mechanism of Action Immunosuppressants; Potassium channel modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Autoimmune disorders; Transplant rejection; Urinary incontinence
Most Recent Events
- 25 Nov 2003 This programme is still in active development
- 22 Jun 2001 M&E Biotech is now called Pharmexa
- 13 Sep 2000 NeuroSearch is collaborating with M&E Biotech on researching the immunosuppressive potential of the potassium channel modulators